Shengnuo Biological Announcement: Wholly-owned subsidiary Shengnuo Pharmaceuticals has signed a "Product Purchase Contract" with a client to supply GLP-1 peptide raw materials, with a contract amount not exceeding RMB 0.35 billion (inclusive of tax). The contract will be established and effective from the date of signing and seal of both parties, and the performance period will be from the date of agreement signing to December 31, 2025. If the contract is successfully implemented, it will help enhance the company's sustainable profitability and have a positive impact on the company's business development and operational performance. However, there may be risks in the performance of the contract due to significant changes in the external macro environment, adjustments to relevant national policies, and other unforeseeable or force majeure factors.